The Fred Hutch Bone Marrow Transplant Program at Seattle Cancer Care Alliance has been recognized by the Center for International Blood and Marrow Transplant Research® (CIBMTR) for outperforming its expected one-year survival rates for allogeneic transplant patients – those who receive donated adult blood-forming stem cells. SCCA’s program is one of only 13 centers around the country receiving this top evaluation and one of only six programs to exceed expectations for at least five years in a row.
Comparing Transplant Centers
To arrive at its findings, CIBMTR® independently examined the survival rates of 23,846 transplant patients treated for blood cancers at U.S. centers in the National Marrow Donor Program® network. The reporting period for the 2017 report covered Jan. 1, 2013 to Dec. 31, 2015. During this three-year period, 795 allogeneic transplants were performed at the Fred Hutch Bone Marrow Program at SCCA and met the criteria for the study.
The report, published annually, is required by federal law and is designed to provide potential stem cell transplant recipients, their families and the public with comparative survival rates among transplant centers.
SCCA’s program was one of 13 centers (7 percent nationally) identified as over-performing. Twenty-one centers’ (12 percent) survival rates were below the expected average, and 140 (80 percent) were average. Only six centers -- including SCCA’s -- had the distinction of being named a top performer for at least five years in a row.
“We expect these superior outcomes are attributable to many factors including a dedication to teamwork combined with decades of transplant experience, ground-breaking research, and care standards that are well defined and evidence-based,” said Dr. Marco Mielcarek, medical director for the Adult Bone Marrow Transplant Program at SCCA, and associate member of the Clinical Research Division at Fred Hutch. “Our efforts have yielded consistent improvements in efficacy and safety of stem cell transplantation and our team is committed to continued improvements in outcomes for our patients.”